These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21268101)
41. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
42. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. Bödeker RH; Madersbacher H; Neumeister C; Zellner M BMC Urol; 2010 Sep; 10():15. PubMed ID: 20840754 [TBL] [Abstract][Full Text] [Related]
43. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Menarini M; Del Popolo G; Di Benedetto P; Haselmann J; Bödeker RH; Schwantes U; Madersbacher H; Int J Clin Pharmacol Ther; 2006 Dec; 44(12):623-32. PubMed ID: 17190372 [TBL] [Abstract][Full Text] [Related]
44. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. Malone-Lee JG; Al-Buheissi S BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469 [TBL] [Abstract][Full Text] [Related]
45. Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled study. Ozdedeli S; Karapolat H; Akkoc Y Clin Rehabil; 2010 Apr; 24(4):342-51. PubMed ID: 20212061 [TBL] [Abstract][Full Text] [Related]
46. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920 [TBL] [Abstract][Full Text] [Related]
47. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446 [TBL] [Abstract][Full Text] [Related]
48. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972 [TBL] [Abstract][Full Text] [Related]
49. [Clinical trial to evaluate trospium chloride (Uraplex) effectiveness and tolerance in patients with detrusor instability incontinence and its impact on quality of life]. Fuertes ME; García Matres MJ; González Romojaro V; de la Rosa S; Anguera Vila A; de la Peña J; Leiva Galvis O; Sánchez Chapado M Arch Esp Urol; 2000 Mar; 53(2):125-36. PubMed ID: 10802918 [TBL] [Abstract][Full Text] [Related]
50. Clinical relevance of health-related quality of life outcomes with darifenacin. Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056 [TBL] [Abstract][Full Text] [Related]
51. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365 [TBL] [Abstract][Full Text] [Related]
52. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Foote J; Glavind K; Kralidis G; Wyndaele JJ Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219 [TBL] [Abstract][Full Text] [Related]
53. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900 [TBL] [Abstract][Full Text] [Related]
54. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. Nitti VW; Rovner ES; Bavendam T BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062 [TBL] [Abstract][Full Text] [Related]
55. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely AD; Lucente V; Vapnek J; Smith N Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526 [TBL] [Abstract][Full Text] [Related]
56. Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z; BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723 [TBL] [Abstract][Full Text] [Related]
59. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Staskin D; Kay G; Tannenbaum C; Goldman HB; Bhashi K; Ling J; Oefelein MG Int J Clin Pract; 2010 Aug; 64(9):1294-300. PubMed ID: 20561092 [TBL] [Abstract][Full Text] [Related]
60. Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial. Geller EJ; Dumond JB; Bowling JM; Khandelwal CM; Wu JM; Busby-Whitehead J; Kaufer DI Female Pelvic Med Reconstr Surg; 2017; 23(2):118-123. PubMed ID: 28067745 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]